83 FR 13487 - Sunshine Act Meetings; Federal Retirement Thrift Investment Board Member Meeting

FEDERAL RETIREMENT THRIFT INVESTMENT BOARD

Federal Register Volume 83, Issue 61 (March 29, 2018)

Page Range		13487-13487
FR Document		2018-06427

Federal Register, Volume 83 Issue 61 (Thursday, March 29, 2018)

[Federal Register Volume 83, Number 61 (Thursday, March 29, 2018)]
[Notices]
[Page 13487]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2018-06427]



[[Page 13487]]

=======================================================================
-----------------------------------------------------------------------

FEDERAL RETIREMENT THRIFT INVESTMENT BOARD


Sunshine Act Meetings; Federal Retirement Thrift Investment Board 
Member Meeting

TIME AND DATE: 4:00 p.m. (telephonic), March 28, 2018.

STATUS: Closed session.

MATTERS TO BE CONSIDERED: Information covered under 5 U.S.C. 552b 
(c)(9)(B).

CONTACT PERSON FOR MORE INFORMATION: Kimberly Weaver, Director, Office 
of External Affairs, (202) 942-1640.

    Dated: March 27, 2018.
Dharmesh Vashee,
Deputy General Counsel, Federal Retirement Thrift Investment Board.
[FR Doc. 2018-06427 Filed 3-27-18; 11:15 am]
BILLING CODE 6760-01-P

Federal Register / Vol. 83, No. 61 / Thursday, March 29, 2018 / Notices 13487

FEDERAL RETIREMENT THRIFT Prevention, 1600 Clifton Road NE, Question and Answer Webinar
INVESTMENT BOARD Mailstop D–42, Atlanta, GA 30329; Individuals interested in this
Telephone (404)639–1330; or email tto@ technology opportunity are invited to
Sunshine Act Meetings; Federal cdc.gov. participate in a live question and
Retirement Thrift Investment Board SUPPLEMENTARY INFORMATION: answer webinar on April 27, 2018 at 10
Member Meeting
a.m. Eastern Daylight Time. Individuals
Description of Technology
TIME AND DATE: 4:00 p.m. (telephonic), must pre-register for the session by
March 28, 2018. CDC Trioplex Real-time RT–PCR sending an email to tto@cdc.gov by
(Reverse Transcription Polymerase Thursday, April 26, at 1 p.m. EDT.
STATUS: Closed session.
Chain Reaction) Assay for Detection of After requesting the registration,
MATTERS TO BE CONSIDERED: Information Zika, Dengue, & Chikungunya Virus participants will receive a confirmation
covered under 5 U.S.C. 552b (c)(9)(B). Infections CDC ref. no.: I–009–17 NIH of their registration along with access
CONTACT PERSON FOR MORE INFORMATION: ref. no.: E–081–2017 (See https:// information to enter prior to the
Kimberly Weaver, Director, Office of www.ott.nih.gov/technology/e-081- webinar. Persons interested in this
External Affairs, (202) 942–1640. 2017.) technology are strongly encouraged to
Dated: March 27, 2018. CDC has developed the Trioplex real- register for and participate in the
Dharmesh Vashee, time RT–PCR test to detect evidence of webinar.
Deputy General Counsel, Federal Retirement Zika, dengue and chikungunya virus A signed Confidential Disclosure
Thrift Investment Board. infections, all of which are spread by Agreement (available under Forms at
[FR Doc. 2018–06427 Filed 3–27–18; 11:15 am] mosquito bites from the same Aedes www.cdc.gov/tto) will be required to
BILLING CODE 6760–01–P species and cause epidemics in more receive copies of unpublished patent
than 100 countries. The real-time RT– applications and other information.
PCR assay is for qualitative detection Inventors: Jorge Munoz-Jordan, Robert
and differentiation of RNA (ribonucleic Lanciotti, and Gilberto Santiago.
DEPARTMENT OF HEALTH AND U.S. PCT (Patent Cooperation Treaty)
HUMAN SERVICES acid) from dengue, chikungunya, and
Zika viruses in serum, whole blood, and Application No. PCT/US2017/023021:
Centers for Disease Control and cerebral spinal fluid, and for the Filed March 17, 2017.
Prevention qualitative detection of Zika virus RNA (CDC Ref. #: I–009–17; NIH Ref. #E–
in urine and amniotic fluid. This assay 081–2017—See https://www.ott.nih.gov/
Government-Owned Inventions; protocol is designed to facilitate technology/e-081-2017.)
Availability for Licensing and simultaneous testing for the three Dated: March 26, 2018.
Collaboration; Notification of Q&A viruses using a single sample in the Sandra Cashman,
Webinar same plate well (multiplex). A Executive Secretary, Centers for Disease
singleplex reaction (measuring one Control and Prevention.
AGENCY: Centers for Disease Control and
analyte at a time) is also an option for [FR Doc. 2018–06306 Filed 3–28–18; 8:45 am]
Prevention (CDC), Department of Health
chikungunya, and dengue testing if one
and Human Services (HHS). BILLING CODE 4163–18–P
primer/probe set per well is preferred.
ACTION: Notice. The test can be run in different
SUMMARY: The invention named in this modalities and equipment available in DEPARTMENT OF HEALTH AND
notice is owned by agencies of the most laboratories. The test has been HUMAN SERVICES
United States Government and is designed to minimize the likelihood of
available for licensing in accordance false positive results. Cross-reactivity for Centers for Medicare & Medicaid
with the U.S. Federal Technology any of the components is not expected. Services
Transfer Act of 1986. Related data for The Food & Drug Administration (FDA)
[Document Identifiers CMS–10148]
510(k) submission is available as part of issued emergency use authorization
the licensing package. The technology (EUA) for the Trioplex assay on March Agency Information Collection
and related data are being licensed to 17, 2016. Additional information can be Activities: Proposed Collection;
achieve expeditious commercialization found at: http://www.fda.gov/ Comment Request
of federally funded research and downloads/MedicalDevices/Safety/
EmergencySituations/UCM491592.pdf. AGENCY: Centers for Medicare &
development. A U.S. Provisional patent
Currently, there are no vaccines or Medicaid Services, HHS.
application has been filed to extend
market coverage. CDC also seeks therapeutics commercially available for ACTION: Notice.
collaboration partners with interest in Zika, dengue, or chikungunya virus
infections. SUMMARY: The Centers for Medicare &
adapting the test for different Medicaid Services (CMS) is announcing
equipment, point-of-care, or more rapid Competitive advantages:
an opportunity for the public to
processing. • Currently, there is no multiplex assay comment on CMS’ intention to collect
DATES: Individuals interested in this on the market that can detect Zika, information from the public. Under the
technology opportunity are invited to chikungunya and the four dengue Paperwork Reduction Act of 1995 (the
participate in a live question and subtypes in one test; this test will also PRA), federal agencies are required to
answer webinar on April 27, 2018 at 10 help assess disease severity in dengue publish notice in the Federal Register
sradovich on DSK3GMQ082PROD with NOTICES

a.m. Eastern Daylight Time. secondary infections concerning each proposed collection of
ADDRESSES: Licensing, related data for • There is no FDA-approved information (including each proposed
510(k) submission, and other chikungunya PCR test on the market extension or reinstatement of an existing
information pertaining to the technology and current Zika and dengue tests collection of information) and to allow
listed below, may be obtained by must be run separately 60 days for public comment on the
writing to Technology Transfer Office, • This was the first molecular test for proposed action. Interested persons are
Centers for Disease Control and Zika to receive FDA’s EUA invited to send comments regarding our

VerDate Sep<11>2014 19:09 Mar 28, 2018 Jkt 244001 PO 00000 Frm 00019 Fmt 4703 Sfmt 4703 E:\FR\FM\29MRN1.SGM 29MRN1

Document Created: 2018-03-29 00:25:58
Document Modified: 2018-03-29 00:25:58

Category		Regulatory Information
Collection		Federal Register
sudoc Class		AE 2.7: GS 4.107: AE 2.106:
Publisher		Office of the Federal Register, National Archives and Records Administration
Section		Notices
Dates		4:00 p.m. (telephonic), March 28, 2018.
FR Citation		83 FR 13487